Abstract:Parkinson's disease (PD), a common degenerative disease in humans, is known to result from loss of dopamine neurons in the substantia nigra and is characterized by severe motor symptoms of tremor, rigidity, bradykinsia and postural instability. Although levodopa administration, surgical neural lesion, and deep brain stimulation have been shown to be effective in improving parkinsonian symptoms, cell replacement therapy such as transplantation of dopamine neurons or neural stem cells has shed new light on an alternative treatment strategy for PD. While the difficulty in securing donor dopamine neurons and the immuno-rejection of neural transplants largely hinder application of neural transplants in clinical treatment, induced pluripotent stem cells (iPS cells) derived from somatic cells may represent a powerful tool for studying the pathogenesis of PD and provide a source for replacement therapies in this neurodegenerative disease. Yamanaka et al. [2006, 2007] first succeeded in generating iPS cells by reprogramming fibroblasts with four transcription factors, Oct4, Sox2, Klf4, and c-Myc in both mouse and human. Animal studies have further shown that iPS cells from fibroblasts could be induced into dopamine neurons and transplantation of these cells within the central nervous system improved motor symptoms in the 6-OHDA model of PD. More interestingly, neural stem cells or fibroblasts from patients can be efficiently reprogrammed and subsequently differentiated into dopamine neurons. Derivation of patient-specific iPS cells and subsequent differentiation into dopamine neurons would provide a disease-specific in vitro model for disease pathology, drug screening and personalized stem cell therapy for PD. This review summarizes current methods and modifications in producing iPS cells from somatic cells as well as safety concerns of reprogramming procedures. Novel reprogramming strategies that deter abnormal permanent genetic and epigenetic alterations are essential for propagating clinically-qualified iPS cells. Future investigation into cell transforming and reprogramming processes are needed to generate the disease-specific iPS cells for personalized regeneration medicine of PD patients by disclosing detailed reprogramming mechanisms.

Generation of integration-free human induced pluripotent stem cells from a patient with sporadic Parkinson's disease

Generation of Induced Pluripotent Stem Cell Line (Zzui007-A) from a 52-Year-old Patient with a Novel CHCHD2 Gene Mutation in Parkinson's Disease.

Generation of an induced pluripotent stem cell line (KNIHi001-A) by reprogramming peripheral blood mononuclear cells isolated from a patient with Parkinson's disease

Generation of naivetropic induced pluripotent stem cells from Parkinson's disease patients for high efficiency genetic manipulation

Generation of an induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient with a pathogenic LRP10/c.688C > T(p.Arg230Trp) mutation

Generation of an induced pluripotent stem cell line (HMSCATi004-A) from an early onset Parkinson's disease patient with PRKN gene mutation

Generation of an Induced Pluripotent Stem Cell Line from the Dermal Fibroblasts of a Patient with Arrhythmogenic Right Ventricular Cardiomyopathy Carrying a PKP2/c.2489+1G > A Mutation

Establishment of Induced Pluripotent Stem Cell Line (Zzui009-A) from an Alzheimer's Disease Patient Carrying a PSEN1 Gene Mutation

Generation of an iPSC line from a 79-year-old female patient diagnosed with sporadic Parkinson's disease

Generation of hiPSCs (JUCGRMi003-A) from a patient with Parkinson's disease with PARK2 mutation

Redefining Parkinson’s Disease Research Using Induced Pluripotent Stem Cells

Generation of a human iPSC line from a Parkinson's disease patient with a novel CHCHD2 mutation (R145Q)

Generation and characterization of induced pluripotent stem cells from a Parkinson's disease patient carrying the digenic LRRK2 p.G2019S and GBA1 p.N409S mutations

Generation of a Human Ipsc Line from a Parkinson’s Disease Patient with a Novel CHCHD2 Mutation (P.r145q)

Generation of induced pluripotent stem cell line (ZZUi027-A) derived from skin fibroblasts from a Parkinson's disease patient with RAB39B gene mutation

Production of a Human Ipsc Line from an Early-Onset Parkinson's Disease Patient with a Novel CHCHD2 Gene Truncated Mutation.

Generation of an Induced Pluripotent Stem Cell Line (Gibhi003-A) from a Parkinson's Disease Patient with Mutant PINK1 (p. I368N).

Generation of induced pluripotent stem cells (NIMHi015-A) from a Parkinson's Disease patient harbouring a homozygous Exon 3 deletion in the PRKN gene

Idiopathic Parkinson's disease patient-derived induced pluripotent stem cells function as midbrain dopaminergic neurons in rodent brains

Potential application of induced pluripotent stem cells in cell replacement therapy for parkinson's disease

iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease